Novartis AG vs Teucrium Soybean Fund — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Teucrium Soybean Fund trades at $25.86. The key difference: Novartis AG pays a 3.17% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SOYB | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $25.88 |
52-Week Low | $113.50 | $21.07 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →